Here, we conducted an in-depth characterisation of the reprogramming capacities of oleuropein over cancer-associated myeloid cells to overcome the resistance to PD-1/PD-L1 blockade immunotherapies associated to these immune cell types. Here, CD274 is linked to cancer.